Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cycurion, Inc.WAVS · Entity 6914 | Director | January 11, 2022 | January 11, 2022 |
| DarioHealth Corp.DRIO · Entity 7024 | Director | September 18, 2025 | September 28, 2026 |
| VivoSim Labs, INC.VIVS · Entity 8386 | Director | January 27, 2026 | January 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cycurion, Inc.
Report date January 11, 2022 · Filed January 11, 2022
This filing explicitly reported no securities owned.
DarioHealth Corp.
Report date September 18, 2025 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy AKS Family Partners L.P. | 17,906 |
Reported balance
After 2025-09-18 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-09-18 · Conversion · Acquired 11,760 · Balance 17,906 F1: Pursuant to the Second Amended and Restated Certificates of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock and the Series D-2 Preferred Stock filed with the Secretary of State of the State of Delaware, the mandatory conversion period of all outstanding shares of each such series was accelerated, and such shares automatically converted into shares of Common Stock effective September 18, 2025, together with all accrued and unpaid dividends, including dividend shares, subject to certain beneficial ownership limitations. F2: AKS Family Partners L.P.'s 250 shares of Series C Preferred Stock automatically converted into 6,189 shares of Common Stock on September 18, 2025, at a conversion price of $40.40 per share. AKS Family Partners L.P. also received 5,571 shares of Common Stock in respect of accrued and unpaid dividends on the Series C Preferred Stock, for a total of 11,760 shares of Common Stock. The conversion occurred after the 20-for-1 reverse stock split effected on August 28, 2025, and all share amounts and prices are reported on a post-split basis. The Series C Preferred Stock was previously reported on the Reporting Person's Form 4 filed in September 2025 as 123,763 shares on a pre-split, as-converted basis. |
| Common StockSEC Table I · non-derivative | IndirectBy AKS Family Partners L.P. | 26,341 |
Reported balance
After 2025-09-18 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-09-18 · Conversion · Acquired 8,435 · Balance 26,341 F1: Pursuant to the Second Amended and Restated Certificates of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock and the Series D-2 Preferred Stock filed with the Secretary of State of the State of Delaware, the mandatory conversion period of all outstanding shares of each such series was accelerated, and such shares automatically converted into shares of Common Stock effective September 18, 2025, together with all accrued and unpaid dividends, including dividend shares, subject to certain beneficial ownership limitations. F3: AKS Family Partners L.P.'s 100 shares of Series D-2 Preferred Stock automatically converted into 6,025 shares of Common Stock on September 18, 2025, at a conversion price of $16.60 per share. AKS Family Partners L.P. also received 2,410 shares of Common Stock in respect of accrued and unpaid dividends on the Series D-2 Preferred Stock, for a total of 8,435 shares of Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 57,717 |
Reported balance
After 2026-09-24 transaction · row 3
1 source rowRow 3 · 2026-09-24 · Grant · Acquired 28,000 · Balance 57,717 F4: The restricted share award shall vest on the last day of the second-year anniversary after the grant date. |
| Series C Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2025-09-18 | IndirectBy AKS Family Partners L.P. | 0 |
Reported balance
After 2025-09-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-09-18 · Conversion · Disposed 250 · Balance 0 F2: AKS Family Partners L.P.'s 250 shares of Series C Preferred Stock automatically converted into 6,189 shares of Common Stock on September 18, 2025, at a conversion price of $40.40 per share. AKS Family Partners L.P. also received 5,571 shares of Common Stock in respect of accrued and unpaid dividends on the Series C Preferred Stock, for a total of 11,760 shares of Common Stock. The conversion occurred after the 20-for-1 reverse stock split effected on August 28, 2025, and all share amounts and prices are reported on a post-split basis. The Series C Preferred Stock was previously reported on the Reporting Person's Form 4 filed in September 2025 as 123,763 shares on a pre-split, as-converted basis. |
| Series D-2 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2025-09-18 | IndirectBy AKS Family Partners L.P. | 0 |
Reported balance
After 2025-09-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-09-18 · Conversion · Disposed 100 · Balance 0 F3: AKS Family Partners L.P.'s 100 shares of Series D-2 Preferred Stock automatically converted into 6,025 shares of Common Stock on September 18, 2025, at a conversion price of $16.60 per share. AKS Family Partners L.P. also received 2,410 shares of Common Stock in respect of accrued and unpaid dividends on the Series D-2 Preferred Stock, for a total of 8,435 shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Second Amended and Restated Certificates of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock and the Series D-2 Preferred Stock filed with the Secretary of State of the State of Delaware, the mandatory conversion period of all outstanding shares of each such series was accelerated, and such shares automatically converted into shares of Common Stock effective September 18, 2025, together with all accrued and unpaid dividends, including dividend shares, subject to certain beneficial ownership limitations.
F2: AKS Family Partners L.P.'s 250 shares of Series C Preferred Stock automatically converted into 6,189 shares of Common Stock on September 18, 2025, at a conversion price of $40.40 per share. AKS Family Partners L.P. also received 5,571 shares of Common Stock in respect of accrued and unpaid dividends on the Series C Preferred Stock, for a total of 11,760 shares of Common Stock. The conversion occurred after the 20-for-1 reverse stock split effected on August 28, 2025, and all share amounts and prices are reported on a post-split basis. The Series C Preferred Stock was previously reported on the Reporting Person's Form 4 filed in September 2025 as 123,763 shares on a pre-split, as-converted basis.
F3: AKS Family Partners L.P.'s 100 shares of Series D-2 Preferred Stock automatically converted into 6,025 shares of Common Stock on September 18, 2025, at a conversion price of $16.60 per share. AKS Family Partners L.P. also received 2,410 shares of Common Stock in respect of accrued and unpaid dividends on the Series D-2 Preferred Stock, for a total of 8,435 shares of Common Stock.
F4: The restricted share award shall vest on the last day of the second-year anniversary after the grant date.
VivoSim Labs, INC.
Report date January 27, 2026 · Filed January 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,899 |
Reported balance
After 2026-01-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-27 · Grant · Acquired 15,000 · Balance 19,899 F1: The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. F2: Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.
F2: Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Matinas BioPharma Holdings, Inc.
Report date October 16, 2025 · Filed August 13, 2026
Section 16 reporting ended · disclosed 2026-08-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 113,450 |
Reported balance
After 2025-10-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-10-31 · Other · Acquired 92,100 · Balance 113,450 F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 743,785 |
Reported balance
After 2026-07-10 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-07-10 · Other · Acquired 630,335 · Balance 743,785 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough A.K.S Family Partners LP | 416,900 |
Reported balance
After 2026-07-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-10 · Other · Acquired 344,710 · Balance 416,900 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2030-04-08 | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 800,000 |
Reported balance
After 2025-10-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-10-16 · Other · Acquired 800,000 · Balance 800,000 F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2030-04-08 | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 630,335 |
Reported balance
After 2025-10-31 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-10-31 · Other · Disposed 92,100 · Balance 630,335 F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2030-04-08 | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 0 |
Reported balance
After 2026-07-10 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-07-10 · Other · Disposed 630,335 · Balance 0 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 630,335 |
Reported balance
After 2026-07-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-07-10 · Grant · Acquired 630,335 · Balance 630,335 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 | IndirectThrough SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern | 265 |
Reported balance
After 2025-10-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-10-16 · Other · Acquired 265 · Balance 265 F5: The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date. F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2030-04-08 | IndirectThrough A.K.S Family Partners LP | 0 |
Reported balance
After 2026-07-10 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-07-10 · Other · Disposed 344,710 · Balance 0 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F4: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 | IndirectThrough A.K.S Family Partners LP | 344,710 |
Reported balance
After 2026-07-10 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-07-10 · Grant · Acquired 344,710 · Balance 344,710 F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received. F4: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 | Direct | 141,462 |
Reported balance
After 2026-07-10 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-07-10 · Other · Acquired 141,462 · Balance 141,462 F3: On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the "Solicitation Agent Warrants") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern. |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 28,260 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 28,260 |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough AKS Family Foundation | 26,500 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 26,500 |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough Pavillion Capital Partners LLC | 6,000 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 6,000 |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough Piper Venture Partners LLC | 6,000 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 6,000 |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough IRA Adam K Stern - Rollover IRA | 1,000 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 1,000 |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectThrough Stern Aegis Ventures LLC 401k Plan for the Benefit of Adam K Stern | 3,000 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 3,000 |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 | IndirectThrough AKS Family Partners | 101 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 101 F5: The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date. F4: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement.
F2: On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the "New Warrants"). The Registrant is required to obtain stockholder approval ("Inducement Stockholder Approval") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received.
F3: On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the "Solicitation Agent Warrants") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern.
F4: On June 10, 2026, Sanitam Parnters LLC ("Sanitam") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant.
F5: The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock Warrant · Derivative | 231,383 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001104659-20-082723 · tm2024537d1_4.xml · derivative · entry 5 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,383 Underlying: Common Stock · 231,383 shares Expires 2024-12-19 F1 · shares: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of such warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. F1 · price: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of such warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | Disposition to issuerCommon Stock Warrant · Derivative | 253,911 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001104659-20-082723 · tm2024537d1_4.xml · derivative · entry 4 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 253,911 shares Expires 2024-12-19 F1 · shares: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of such warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. F1 · price: The two reported transactions involved an amendment of an outstanding common stock warrant pursuant to a transfer of a portion of such warrant with Michael Siek, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant was originally issued on December 19, 2019. Read SEC document |
| July 03, 2020 Filed Jul 6, 2020 20:10 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 639 | $6.66 | $4,255.74 |
DisclosureSEC source: 0001104659-20-081207 · tm2024118-2_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,049 F1 · shares: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of July 2020. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 01:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011758 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,281,983 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock. F2 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 500 | $5.91 | $2,955.00 |
DisclosureSEC source: 0001104659-20-071370 · tm2022156d2_4.xml · nonDerivative · entry 3 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · AKS Family Partners Disclosed balance after: 15,500 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.86 to $5.94, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 500 | $5.88 | $2,940.00 |
DisclosureSEC source: 0001104659-20-071370 · tm2022156d2_4.xml · nonDerivative · entry 2 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · AKS Family Foundation, Inc. Disclosed balance after: 2,500 Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 1,500 | $5.89 | $8,835.00 |
DisclosureSEC source: 0001104659-20-071370 · tm2022156d2_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,410 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.70 to $5.96, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 639 | $6.66 | $4,255.74 |
DisclosureSEC source: 0001104659-20-070282 · tm2021817d1_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,910 F1 · shares: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of June 2020. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 639 | $6.66 | $4,255.74 |
DisclosureSEC source: 0001104659-20-058794 · tm2018953d1_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,271 F1 · shares: The reporting person was awarded such securities in exchange for waivinglieu of consulting fees owed for the month of May 2020. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:29 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 639 | $6.66 | $4,255.74 |
DisclosureSEC source: 0001104659-20-049736 · tm2016474d1_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,993 F1 · shares: The reporting person was awarded such securities in exchange for waiving consulting fees owed for the month of April 2020. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 493 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-044151 · tm2015091d2_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,993 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the month of March 2020. Read SEC document |
| April 03, 2020 Filed Apr 8, 2020 20:38 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | Exercise / conversionWarrant (right to buy) · Derivative | 952,676 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001493152-20-006066 · ownership.xml · derivative · entry 8 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 952,676 shares Expires 2020-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2020 Filed Apr 8, 2020 20:38 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | Exercise / conversionCommon Stock, par value $0.0001 per share | 278,407 | $0.50 | $139,203.50 |
DisclosureSEC source: 0001493152-20-006066 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,337,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On April 3, 2020, the reporting person exercised a warrant to purchase 952,676 shares of Matinas BioPharma Holdings, Inc. common stock for $0.50 a share. The reporting person paid the exercise price on a cashless basis, resulting in Matinas BioPharma Holdings, Inc.'s withholding of 674,269 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 278,407 shares. The value of the shares cancelled was $0.7065 per share, which represents the average closing price of the shares for the 20 trading days immediately preceding the date of exercise. Read SEC document |
| March 20, 2020 Filed Mar 23, 2020 11:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 14,500 | $3.80 | $55,100.00 |
DisclosureSEC source: 0001104659-20-037061 · tm2013458d1_4.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.44 to $4.30, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 14:51 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 10,000 | $0.65 | $6,500.00 |
DisclosureSEC source: 0001493152-20-004196 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by SternAegis Ventures, LLC 401(k) Profit Sharing Plan Disclosed balance after: 10,000 F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.64 to $0.65, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 107,416 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001493152-19-016457 · ownership.xml · derivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,416 Underlying: Common Stock · 107,416 shares Expires 2029-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 13:45 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 10,400 | $0.70 | $7,267.52 |
DisclosureSEC source: 0000905718-19-000718 · matinasbio_fm4aug192019.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804,392 F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.69 to $0.70, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| July 29, 2019 Filed Oct 2, 2019 22:08 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | ConversionSeries A Preferred Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014911 · ownership.xml · derivative · entry 10 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: Converts automatically into Common Stock upon the earlier of (i) notice by the Issuer to the holders that the Issuer elected to convert all outstanding shares of Class A Preferred, (ii) July 29, 2019, (iii) the approval of the Issuer's MAT2203 product candidate by the U.S. Food and Drug Administration or the European Medicines Agency (the "Regulatory Approval") or (iv) the Regulatory Approval of the Issuer's MAT2501 product candidate. Read SEC document |
| July 26, 2019 Filed Oct 2, 2019 22:08 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014911 · ownership.xml · nonDerivative · entry 2 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052,392 F1 · kind: Stock dividend, payable to all holders of record of Series A Preferred Stock of 2.4 shares of Common Stock for each share of Series A Preferred Stock. Read SEC document |
| July 26, 2019 Filed Oct 2, 2019 22:08 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | ConversionCommon Stock, par value $0.0001 per share | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014911 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 993,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2019 Filed Oct 2, 2019 22:08 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014911 · ownership.xml · nonDerivative · entry 4 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,256,483 F2 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock. F3 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 14:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 15,000 | $0.80 | $12,000.00 |
DisclosureSEC source: 0001493152-19-009354 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,239,483 F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 16:49 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 20,000 | $0.80 | $15,998.00 |
DisclosureSEC source: 0001493152-19-009097 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,224,483 F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.7966 to $0.8021, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 21:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 15,000 | $0.82 | $12,300.00 |
DisclosureSEC source: 0001493152-19-009014 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,204,483 F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.79 to $0.83, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 21:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 20,000 | $0.89 | $17,800.00 |
DisclosureSEC source: 0001493152-19-008941 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,189,483 F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 80,000 | $0.94 | $75,200.00 |
DisclosureSEC source: 0001493152-19-008568 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,169,483 F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.92 to $0.95, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| May 16, 2019 Filed May 20, 2019 22:40 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 150,000 | $0.95 | $142,500.00 |
DisclosureSEC source: 0001493152-19-007949 · ownership.xml · nonDerivative · entry 5 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,089,483 F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.92 to $0.95, inclusive. Upon request of the SEC staff, the reporting person will provide full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| March 19, 2019 Filed Oct 2, 2019 22:08 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 6,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014911 · ownership.xml · nonDerivative · entry 3 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,992 Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 13:17 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 128,299 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000905718-18-000908 · ownership.xml · derivative · entry 2 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,299 Underlying: Common Stock · 128,299 shares Expires 2028-10-31 Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 13:17 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 128,299 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000905718-18-000908 · ownership.xml · derivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,299 Underlying: Common Stock · 128,299 shares Expires 2028-10-31 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2018. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:36 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseSeries B Convertible Preferred Stock · Derivative | 85 | $1,000.00 Strike: $0.50 | $85,000.00 |
DisclosureSEC source: 0000905718-18-000588 · stern_matinas-fm4jun212018.xml · derivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 85 Underlying: Common Stock · 170,000 shares Expires not disclosed F1 · derivative.exercise_date: On June 21, 2018, AKS Family Partners LP purchased 85 shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F1 · derivative.expiration_date: On June 21, 2018, AKS Family Partners LP purchased 85 shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F2 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| December 27, 2017 Filed Dec 29, 2017 21:39 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-17-001060 · stern_fm4dec272017.xml · nonDerivative · entry 5 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 2,939,483 F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| December 27, 2017 Filed Dec 29, 2017 21:39 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-17-001060 · stern_fm4dec272017.xml · nonDerivative · entry 4 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Foundation, Inc. Disclosed balance after: 1,750,000 F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 13:03 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 50,000 | $1.38 | $69,000.00 |
DisclosureSEC source: 0000905718-17-000831 · stern_fm4sept72017.xml · nonDerivative · entry 6 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,689,483 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.39, inclusive. The reporting person undertakes to provide Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 13:03 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 50,000 | $1.38 | $69,000.00 |
DisclosureSEC source: 0000905718-17-000831 · stern_fm4sept72017.xml · nonDerivative · entry 5 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,639,483 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.40, inclusive. The reporting person undertakes to provide Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4. F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| July 29, 2016 Filed Oct 2, 2019 22:08 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseSeries A Preferred Stock · Derivative | 20,000 | $5.00 Strike: $0.00 | $100,000.00 |
DisclosureSEC source: 0001493152-19-014911 · ownership.xml · derivative · entry 9 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F4 · derivative.expiration_date: Converts automatically into Common Stock upon the earlier of (i) notice by the Issuer to the holders that the Issuer elected to convert all outstanding shares of Class A Preferred, (ii) July 29, 2019, (iii) the approval of the Issuer's MAT2203 product candidate by the U.S. Food and Drug Administration or the European Medicines Agency (the "Regulatory Approval") or (iv) the Regulatory Approval of the Issuer's MAT2501 product candidate. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.